Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ilia Atanelishvili"'
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0188588 (2017)
M10 is a ten amino acid peptide generated from the intracellular cytoplasmic tail of the hepatocyte growth factor (HGF) receptor c-Met following cleavage by caspase-3. Recently we reported that M10 interacts with Smad2 and demonstrates antifibrotic p
Externí odkaz:
https://doaj.org/article/0baebbadc75d4460a4a9c418447d7479
Autor:
Ilia Atanelishvili, Yuichiro Shirai, Tanjina Akter, Atsushi Noguchi, Kurt T Ash, Suniti Misra, Sibnath Ghatak, Richard M Silver, Galina S Bogatkevich
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0162357 (2016)
Pulmonary fibrosis represents the terminal stage of a diverse group of lung diseases including scleroderma associated interstitial lung disease. The molecular mechanisms underlying the pathogenesis of lung fibrosis are not well understood and there i
Externí odkaz:
https://doaj.org/article/fbdd59dbc84a4b79b18571acc481c7a0
Autor:
Suniti Misra, Vincent C. Hascall, Ilia Atanelishvili, Ricardo Moreno Rodriguez, Roger R. Markwald, Shibnath Ghatak
Publikováno v:
International Journal of Cell Biology, Vol 2015 (2015)
The outcome of patients with cancer has improved significantly in the past decade with the incorporation of drugs targeting cell surface adhesive receptors, receptor tyrosine kinases, and modulation of several molecules of extracellular matrices (ECM
Externí odkaz:
https://doaj.org/article/c607f91182aa4a09a0f6a5c192957657
Autor:
Shibnath Ghatak, Edward V. Maytin, Judith A. Mack, Vincent C. Hascall, Ilia Atanelishvili, Ricardo Moreno Rodriguez, Roger R. Markwald, Suniti Misra
Publikováno v:
International Journal of Cell Biology, Vol 2015 (2015)
A wound is a type of injury that damages living tissues. In this review, we will be referring mainly to healing responses in the organs including skin and the lungs. Fibrosis is a process of dysregulated extracellular matrix (ECM) production that lea
Externí odkaz:
https://doaj.org/article/3179f5e10a2a4a618e01f05728443efd
Publikováno v:
Arthritis & Rheumatology. 75:438-448
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05b71be9077499b2eb185a07bb2752b0
https://doi.org/10.1002/art.42344
https://doi.org/10.1002/art.42344
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.).
Interstitial lung disease (ILD) is a serious complication and leading cause of mortality in patients with systemic sclerosis (SSc). In the current study we explored the role of LMCD1 (LIM and cysteine-rich domains-1) as a novel factor in the pathogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::18dfa97adcef653bcd89bbc567c21a0a
https://pubmed.ncbi.nlm.nih.gov/36103378
https://pubmed.ncbi.nlm.nih.gov/36103378
Autor:
K Kajdasz, Paul J. Nietert, Ilia Atanelishvili, Dulaney A. Wilson, Kristin B. Highland, Galina S. Bogatkevich, Tanjina Akter, John T. Huggins, Richard M. Silver
Publikováno v:
Acr Open Rheumatology
ACR Open Rheumatology, Vol 1, Iss 7, Pp 403-411 (2019)
ACR Open Rheumatology, Vol 1, Iss 7, Pp 403-411 (2019)
Objective Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) (scleroderma) and the leading cause of scleroderma-related deaths. There exists an unmet need for a new drug therapy for ILD-complicated SSc. Substantial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55b739cdebc0c37f25c6d9c3668f3f92
https://doi.org/10.1002/acr2.11049
https://doi.org/10.1002/acr2.11049
Autor:
Roger R. Markwald, Galina S. Bogatkevich, Ilia Atanelishvili, Richard M. Silver, Monika Gooz, Vincent C. Hascall, Shibnath Ghatak, Carol Feghali-Bostwick, Jeanette Marjorie Wood, Carol M. Artlett, Victor J. Thannickal, Suniti Misra
Publikováno v:
Journal of Biological Chemistry. 292:10490-10519
Idiopathic pulmonary fibrosis (IPF) is a progressive clinical syndrome of fatal outcome. The lack of information about the signaling pathways that sustain fibrosis and the myofibroblast phenotype has prevented the development of targeted therapies fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df27078f3cc9df921174215e449a5d4e
https://doi.org/10.1074/jbc.m116.752469
https://doi.org/10.1074/jbc.m116.752469
Autor:
S.L. Wollin, Ilia Atanelishvili, Tanjina Akter, Richard M. Silver, Galina S. Bogatkevich, Atsushi Noguchi
Publikováno v:
C62. FIBROBLAST BIOLOGY.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34844166ea25d3532f70fe5177e69a42
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5345
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5345
Autor:
Ilia, Atanelishvili, Tanjina, Akter, Atsushi, Noguchi, Olha, Vuyiv, Lutz, Wollin, Richard M, Silver, Galina S, Bogatkevich
Publikováno v:
Clinical and experimental rheumatology. 37(4)
Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF) and was demonstrated to slow disease progression in patients with IPF by reducing decline in forced vital capacity by 50%. Recently, nintedanib has been reported to exert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a32f72f2496f90b762dd65db3b12684e
https://pubmed.ncbi.nlm.nih.gov/31573469
https://pubmed.ncbi.nlm.nih.gov/31573469